Atherosclerosis - Pipeline Review, H2 2018

Publisher Name :
Date: 11-Sep-2018
No. of pages: 244
Inquire Before Buying

Atherosclerosis - Pipeline Review, H2 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Atherosclerosis - Pipeline Review, H2 2018, provides an overview of the Atherosclerosis (Cardiovascular) pipeline landscape.

Atherosclerosis (or arteriosclerotic vascular disease) is a condition where the arteries become narrowed and hardened due to an excessive build up of plaque around the artery wall. The disease disrupts the flow of blood around the body, posing serious cardiovascular complications. Symptoms of atherosclerosis are chest pain (angina), pain in the leg, arm, and anywhere else that an artery is blocked, shortness of breath, fatigue, confusion (if the blockage affects circulation to the brain) and muscle weakness in the legs from lack of circulation.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Atherosclerosis - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Atherosclerosis (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Atherosclerosis (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Atherosclerosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 4, 3, 4, 46, 10 and 1 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 20 and 2 molecules, respectively.

Atherosclerosis (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Atherosclerosis (Cardiovascular).

- The pipeline guide reviews pipeline therapeutics for Atherosclerosis (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Atherosclerosis (Cardiovascular) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Atherosclerosis (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Atherosclerosis (Cardiovascular)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Atherosclerosis (Cardiovascular).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Atherosclerosis (Cardiovascular) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Atherosclerosis - Pipeline Review, H2 2018

Table of Contents
Table of Contents 2
Introduction 5
Atherosclerosis - Overview 6
Atherosclerosis - Therapeutics Development 7
Atherosclerosis - Therapeutics Assessment 21
Atherosclerosis - Companies Involved in Therapeutics Development 33
Atherosclerosis - Drug Profiles 50
Atherosclerosis - Dormant Projects 203
Atherosclerosis - Discontinued Products 212
Atherosclerosis - Product Development Milestones 215
Appendix 234

List of Tables
Number of Products under Development for Atherosclerosis, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Products under Development by Companies, H2 2018
Products under Development by Universities/Institutes, H2 2018
Products under Development by Universities/Institutes, H2 2018 (Contd..1), H2 2018
Number of Products by Stage and Target, H2 2018
Number of Products by Stage and Target, H2 2018 (Contd..1), H2 2018
Number of Products by Stage and Target, H2 2018 (Contd..2), H2 2018
Number of Products by Stage and Mechanism of Action, H2 2018
Number of Products by Stage and Mechanism of Action, H2 2018 (Contd..1), H2 2018
Number of Products by Stage and Mechanism of Action, H2 2018 (Contd..2), H2 2018
Number of Products by Stage and Route of Administration, H2 2018
Number of Products by Stage and Molecule Type, H2 2018
Atherosclerosis - Pipeline by Ache Laboratorios Farmaceuticos SA, H2 2018
Atherosclerosis - Pipeline by AFFiRiS AG, H2 2018
Atherosclerosis - Pipeline by Amgen Inc, H2 2018
Atherosclerosis - Pipeline by Annexin Pharmaceuticals AB, H2 2018
Atherosclerosis - Pipeline by AstraZeneca Plc, H2 2018
Atherosclerosis - Pipeline by Athera Biotechnologies AB, H2 2018
Atherosclerosis - Pipeline by Boehringer Ingelheim GmbH, H2 2018
Atherosclerosis - Pipeline by Cardax Inc, H2 2018
Atherosclerosis - Pipeline by Cerenis Therapeutics Holding SA, H2 2018
Atherosclerosis - Pipeline by ChemoCentryx Inc, H2 2018
Atherosclerosis - Pipeline by CohBar Inc, H2 2018
Atherosclerosis - Pipeline by Daiichi Sankyo Co Ltd, H2 2018
Atherosclerosis - Pipeline by DoNatur GmbH, H2 2018
Atherosclerosis - Pipeline by Dybly AG, H2 2018
Atherosclerosis - Pipeline by Esperion Therapeutics Inc, H2 2018
Atherosclerosis - Pipeline by GenKyoTex SA, H2 2018
Atherosclerosis - Pipeline by GlaxoSmithKline Plc, H2 2018
Atherosclerosis - Pipeline by Immusoft Corp, H2 2018
Atherosclerosis - Pipeline by Inotrem SA, H2 2018
Atherosclerosis - Pipeline by Inspyr Therapeutics Inc, H2 2018
Atherosclerosis - Pipeline by Iproteos SL, H2 2018
Atherosclerosis - Pipeline by KineMed Inc, H2 2018
Atherosclerosis - Pipeline by Kowa Co Ltd, H2 2018
Atherosclerosis - Pipeline by LG Chem Ltd, H2 2018
Atherosclerosis - Pipeline by LipimetiX Development Inc, H2 2018
Atherosclerosis - Pipeline by MedImmune LLC, H2 2018
Atherosclerosis - Pipeline by NuSirt Biopharma Inc, H2 2018
Atherosclerosis - Pipeline by Omeros Corp, H2 2018
Atherosclerosis - Pipeline by Regeneron Pharmaceuticals Inc, H2 2018
Atherosclerosis - Pipeline by Shin Poong PharmCo Ltd, H2 2018
Atherosclerosis - Pipeline by The Medicines Company, H2 2018
Atherosclerosis - Pipeline by Tolerys SA, H2 2018
Atherosclerosis - Pipeline by Vascular Biogenics Ltd, H2 2018
Atherosclerosis - Pipeline by Vicore Pharma AB, H2 2018
Atherosclerosis - Pipeline by XBiotech Inc, H2 2018
Atherosclerosis - Dormant Projects, H2 2018

List of Figures
Number of Products under Development for Atherosclerosis, H2 2018
Number of Products under Development by Companies, H2 2018
Number of Products under Development by Universities/Institutes, H2 2018
Number of Products by Top 10 Targets, H2 2018
Number of Products by Stage and Top 10 Targets, H2 2018
Number of Products by Top 10 Mechanism of Actions, H2 2018
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018
Number of Products by Routes of Administration, H2 2018
Number of Products by Stage and Routes of Administration, H2 2018
Number of Products by Top 10 Molecule Types, H2 2018
Number of Products by Stage and Top 10 Molecule Types, H2 2018
  • Global (United States, European Union and China) Digoxin Market Research Report 2019-2025
    Published: 14-Jun-2019        Price: US 3280 Onwards        Pages: 111
    In 2019, the market size of Digoxin is million US$ and it will reach million US$ in 2025, growing at a CAGR of from 2019; while in China, the market size is valued at xx million US$ and will increase to xx million US$ in 2025, with a CAGR of xx% during forecast period. In this report, 2018 has been considered as the base year and 2019 to 2025 as the forecast period to estimate the market size for Digoxin. This report studies the global market size of Digoxin, especially fo......
  • Global Myocardial Infarction Drugs Market Insights, Forecast to 2025
    Published: 13-Jun-2019        Price: US 3900 Onwards        Pages: 114
    Myocardial infarction, commonly known as heart attack, occurs due to reduced blood flow to a part of the heart, causing damage to the heart muscle. The medications, which are used to treat heart attacks are known as myocardial infarction drugs. The reduced blood flow further causes blockage in the supply of oxygen to the heart, which is due to atherosclerosis, a process in which the plaque is formed on the inside wall of the coronary vein or one of its minor branches. Myocardial infraction occur......
  • Global Simvastatin Market Research Report 2012-2024
    Published: 11-Jun-2019        Price: US 1800 Onwards        Pages: 72
    Summary The global Simvastatin market will reach xxx Million USD in 2019 with CAGR xx% 2019-2024. The objective of report is to define, segment, and project the market on the basis of product type, application, and region, and to describe the content about the factors influencing market dynamics, policy, economic, technology and market entry etc. Based on products type, the report describes major products type share of regional market. Products mentioned as follows:......
  • Global Rosuvastatin Market Research Report 2012-2024
    Published: 10-Jun-2019        Price: US 1800 Onwards        Pages: 72
    Summary The global Rosuvastatin market will reach xxx Million USD in 2019 with CAGR xx% 2019-2024. The objective of report is to define, segment, and project the market on the basis of product type, application, and region, and to describe the content about the factors influencing market dynamics, policy, economic, technology and market entry etc. Based on products type, the report describes major products type share of regional market. Products mentioned as follows......
  • Global Pitavastatin Market Research Report 2012-2024
    Published: 07-Jun-2019        Price: US 1800 Onwards        Pages: 74
    Summary The global Pitavastatin market will reach xxx Million USD in 2019 with CAGR xx% 2019-2024. The objective of report is to define, segment, and project the market on the basis of product type, application, and region, and to describe the content about the factors influencing market dynamics, policy, economic, technology and market entry etc. Based on products type, the report describes major products type share of regional market. Products mentioned as follows......
  • Global Digoxin Market 2019 by Manufacturers, Regions, Type and Application, Forecast to 2024
    Published: 06-Jun-2019        Price: US 3480 Onwards        Pages: 117
    Scope of the Report: The worldwide market for Digoxin is expected to grow at a CAGR of roughly over the next five years, will reach million US$ in 2024, from million US$ in 2019, according to a new GIR (Global Info Research) study. This report focuses on the Digoxin in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application. Mar......
  • Global Heart Failure Drugs Market Insights, Forecast to 2025
    Published: 05-Jun-2019        Price: US 3900 Onwards        Pages: 115
    The global heart failure drugs market is generic in nature; as many generic drug manufacturers and pharmaceutical giants are providing drugs for a disease. However; the arrival of innovative drugs such as EOM, is expected to change the market dynamics. AstraZeneca and Novartis hold the major share of the global heart failure drugs market with their drugs Toprol-XL and wog, respectively. The companies also hold a strong pipeline and are expected to remain the market leaders during the forecast pe......
  • Myocardial Ischemia Drugs Market Research: Global Status & Forecast by Geography, Type & Application (2015-2025)
    Published: 04-Jun-2019        Price: US 2280 Onwards        Pages: 55
    According to 99Strategy, the Global Myocardial Ischemia Drugs Market is estimated to reach xxx million USD in 2019 and projected to grow at the CAGR of xx% during the 2020-2025. The report analyses the global Myocardial Ischemia Drugs market, the market size and growth, as well as the major market participants. The analysis includes market size, upstream situation, market segmentation, market segmentation, price & cost and industry environment. In addition, the report outlines the......
  • Myocardial Infarction Drugs Market Research: Global Status & Forecast by Geography, Type & Application (2015-2025)
    Published: 04-Jun-2019        Price: US 2280 Onwards        Pages: 58
    According to 99Strategy, the Global Myocardial Infarction Drugs Market is estimated to reach xxx million USD in 2019 and projected to grow at the CAGR of xx% during the 2020-2025. The report analyses the global Myocardial Infarction Drugs market, the market size and growth, as well as the major market participants. The analysis includes market size, upstream situation, market segmentation, market segmentation, price & cost and industry environment. In addition, the report outlines......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs